Here are four key points from their growth strategy:
• For the company as a whole, the management board expects sales to total between $37.6 million and $39.9 million.
• The company forecasts EBITDA in the financial year 2015 of between $2.8 million and $3.9 million.
• For the full year 2015 the company anticipates trauma sales growth to be between $16.9 million and $17.5 million. Its LOQTEQ product family is expected to be the main driver of this development.
• Sales in the biomaterials business are expected to grow by 10 percent.
The company is also still in talks with selected strategic investors and private equity companies on a transaction for aap Biomaterials that is anticipated in the first quarter of 2015.
More articles on devices:
27 spine devices receive FDA 510(k) clearance in January
MiMedx withdraws complaint against Organogenesis
NuVasive COO sells 15k shares — 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
